For research use only
| Cat No. | ABC-SC2064 |
| Product Type | Human iPSCs |
| Cell Type | Induced Pluripotent Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Fibroblast |
| Disease | Congenital Disorder Of Deglycosylation |
| Storage | Liquid Nitrogen |
Employ HighQC™ Human IPSC From Fibroblast-Congenital Disorder Of Deglycosylation for rare genetic disease modeling, drug testing, and molecular studies.
HighQC™ Human IPSC From Fibroblast-Congenital Disorder of Deglycosylation is a disease-specific human induced pluripotent stem cell line derived from dermal fibroblasts of a donor diagnosed with a Congenital Disorder of Deglycosylation (CDDG), a group of rare inherited metabolic diseases characterized by defects in glycoprotein synthesis. The resulting iPSCs (induced pluripotent stem cells) exhibit adherent growth with a high nucleus-to-cytoplasm ratio. They maintain pluripotency and model CDDG-related glycosylation traits. These cells retain the fundamental capacity for trilineage differentiation into cell types of the ectoderm, mesoderm, and endoderm germ layers. They express the core pluripotency marker SSEA-4. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | HighQC™ Human IPSC From Fibroblast-Congenital Disorder Of Deglycosylation, HighQC™ hiPSC CDG, hiPSC-CDG, HighQC™ Human Induced Pluripotent Stem Cells From Fibroblast-Congenital Disorder Of Deglycosylation |
| Species | Human |
| Cat.No | ABC-SC2064 |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Induced Pluripotent Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Fibroblast |
| Disease | Congenital Disorder Of Deglycosylation |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
| Gene Info | CACNA1S NGLY1 |
HighQC™ Human IPSC From Fibroblast-Congenital Disorder of Deglycosylation provides a patient-specific model for in vitro studies of glycoprotein metabolism and disease pathogenesis. Its pluripotent capacity enables directed differentiation into diverse lineages such as hepatocytes, cardiomyocytes, and neuronal cells to investigate the cellular and tissue-specific consequences of glycosylation defects. This system is used to model disease mechanisms, study early developmental pathways affected by protein glycosylation, and serve as a platform for compound screening to identify potential therapeutic agents targeting this metabolic disorder.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).